Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2, while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-14T15:28:51.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T14:59:15.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of study content. This indicates an access restriction or site issue preventing loading of the record.
    Difference
    17%
    Check dated 2026-09-23T20:22:59.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.6 to v3.7.0, indicating a site-level update; no changes to the study information or its presentation are reflected in this diff.
    Difference
    0.1%
    Check dated 2026-09-16T20:04:31.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The page's revision tag in the footer updated from v3.6.5 to v3.6.6, indicating a new build of the site. This behind-the-scenes update is related to the page version and does not modify the study details.
    Difference
    0.1%
    Check dated 2026-09-02T19:37:34.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    The page shows a revised revision label, updating from v3.6.4 to v3.6.5 to reflect a minor backend update to the site.
    Difference
    0.1%
    Check dated 2026-08-12T09:27:20.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.